XBIO Snapshot del titolo
Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$3.81
Capitalizzazione di Mercato
—
P/E (TTM)
-1.4
EPS (TTM)
$-1.58
Ricavi (TTM)
$3M
Rendimento div.
—
ROE
—
D/E Debito/Patrimonio
—
Intervallo 52 sett.
$2 – $14
XBIO Grafico del prezzo delle azioni
OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Medie mobili e sovrapposizioni
Volume
Oscillatori
Momentum e tendenza
Configure
Performance decennale
Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto$3M
2016-12-31→2025-12-31
EPS$-1.58
2021-12-31→2025-12-31
Flusso di cassa libero—
Margini—
Valutazione
Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
XBIO
Mediana dei peer
P/E (TTM)
-1.4
—
Redditività
Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
XBIO
Mediana dei peer
Salute finanziaria
Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
XBIO
Mediana dei peer
Crescita
Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
XBIO
Mediana dei peer
Revenue YoY (Ricavi YoY)
19.0%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
20.4%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
46.8%
—
Metriche per Azione
EPS, valore contabile per azione, flusso di cassa per azione, dividendo per azione
Metrica
Tendenza 5 anni
XBIO
Mediana dei peer
EPS (Diluted) (EPS (Diluito))
$-1.58
—
Efficienza del Capitale
Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
XBIO
Mediana dei peer
XBIO Consenso degli analisti
Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
VENDI6 analisti
Acquisto forte
00,0%
Compra
00,0%
Mantieni
350,0%
Vendi
116,7%
Vendita forte
233,3%
Cronologia utili
EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-0.07%
Periodo
EPS Actual
EPS Stimato
Sorpresa
30 Giugno 2025
$-0.45
$-0.65
0.20%
31 Marzo 2025
$-0.59
$-0.73
0.14%
31 Dicembre 2024
$-0.68
$-0.20
-0.48%
30 Settembre 2024
$-0.28
$-0.14
-0.14%
Confronto Peer (GICS sub-settore industriale)
Metriche chiave rispetto ai pari del settore
Ticker
Capitalizzazione di Mercato
P/E
Rev YoY
Margine Netto
ROE
Margine lordo
XBIO
—
-1.4
19.0%
—
—
—
BOLT
$11M
-0.3
0.07%
-433.7%
-102.2%
—
AQB
$4M
-0.2
-21.2%
—
-315.5%
—
CDIO
—
—
—
—
—
—
PMCB
$8M
-0.3
—
—
-56.7%
—
DRMA
—
—
—
—
—
—
BRTX
$10M
-0.7
-10.3%
-3959.4%
-547.6%
93.4%
BCAB
—
-0.6
—
—
—
—
LABT
—
—
—
—
—
—
Fondamentali Completi
Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico17
Dati annuali Conto Economico per XBIO
Metrica
Tendenza
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue
$3M
$3M
$3M
$2M
$1M
$436.9K
$17.1K
$0
$8M
$3M
$0
$0
Cost of Revenue
·
·
·
·
·
·
·
·
·
·
·
$0
Gross Profit
·
·
·
·
·
·
·
·
·
·
·
$0
R&D Expense
$3M
$3M
$3M
$5M
$3M
$2M
$5M
$3M
$4M
$44M
$3M
$6M
SG&A Expense
$3M
$3M
$4M
$4M
$4M
$3M
$5M
$4M
$7M
$7M
$6M
$7M
Operating Expenses
$6M
$7M
$7M
$8M
$7M
$14M
$13M
$7M
·
·
·
$13M
Operating Income
$-3M
$-4M
$-5M
$-7M
$-6M
$-14M
$-13M
$-7M
$-4M
$-47M
$-10M
$-13M
Interest Expense
·
·
·
·
·
·
·
·
$1.8K
$729.6K
$267.0K
$4.7K
Interest Income
·
·
·
·
·
·
·
·
·
·
·
$19.0K
Other Non-op
$5.7K
$-5.7K
$25.4K
$-1.6K
$1.1K
$-492
$3.3K
$-24.6K
$-24.6K
$-85.4K
$-235.4K
$-326.9K
Pretax Income
·
·
·
·
·
·
·
·
·
·
·
$-14M
Income Tax
$0
$0
$0
$0
$0
$-3M
$0
$0
$0
$0
$0
$0
Net Income
$-3M
$-4M
$-4M
$-7M
$-6M
$-11M
$-13M
$-7M
$-4M
$-54M
$-13M
$-14M
EPS (Basic)
$-1.58
$-2.57
$-2.71
$-4.61
$-0.55
·
·
·
·
·
·
·
EPS (Diluted)
$-1.58
$-2.57
$-2.71
$-4.61
$-0.55
·
·
·
·
·
·
·
Shares (Basic)
1,701,571
1,541,339
1,528,210
1,422,443
10,279,408
·
·
·
·
·
·
·
Shares (Diluted)
1,701,571
1,541,339
1,528,210
1,422,443
10,279,408
·
·
·
·
·
·
·
Stato Patrimoniale25
Dati annuali Stato Patrimoniale per XBIO
Metrica
Tendenza
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Cash & Equivalents
$8M
$6M
$9M
$13M
$18M
$12M
$10M
$571.6K
$6M
$4M
$132.2K
$3M
Receivables
·
·
·
·
·
·
·
·
$0
$3M
$0
·
Prepaid Expense
$166.3K
$422.0K
$603.8K
$556.1K
$479.4K
$842.0K
$722.1K
$555.9K
$285.0K
$1M
$247.3K
$204.0K
Current Assets
$8M
$7M
$10M
$14M
$19M
$12M
$11M
$1M
$6M
$8M
$4M
$3M
PP&E (Net)
·
·
·
$0
$0
$0
$757
$5.0K
$27.8K
$42.4K
$62.0K
$119.4K
PP&E (Gross)
·
·
·
$0
$50.2K
$57.0K
$57.0K
$89.4K
$358.3K
$349.1K
$332.3K
$586.1K
Accum. Depreciation
·
·
·
$0
$50.2K
$57.0K
$56.3K
$84.4K
$330.5K
$306.7K
$270.2K
$466.7K
Goodwill
·
·
·
·
·
$0
$9M
$3M
$3M
$3M
$3M
$3M
Other Non-current Assets
$313.9K
$313.9K
$1M
$1M
$1M
$810.0K
$1M
$705.7K
$724.7K
$66.3K
$129.3K
$199.3K
Total Assets
$8M
$7M
$11M
$15M
$20M
$13M
$22M
$14M
$19M
$21M
$17M
$16M
Accounts Payable
$258.1K
$283.6K
$240.8K
$287.4K
$362.5K
$327.4K
$931.1K
$934.1K
$786.8K
$1M
$2M
$852.8K
Accrued Liabilities
$709.9K
$610.6K
$568.8K
$785.8K
$1M
$574.0K
$464.0K
$664.0K
$1M
$838.9K
$1M
$1M
Current Liabilities
$968.0K
$894.3K
$809.6K
$1M
$1M
$936.9K
$1M
$2M
$2M
$2M
$7M
$3M
Capital Leases
·
·
·
·
·
$27.0K
$0
·
·
·
·
·
Deferred Tax
·
·
·
·
·
$27.0K
$3M
$3M
$3M
$3M
$3M
$3M
Other Non-current Liabilities
·
·
·
·
·
·
·
$0
$0
$19.9K
$38.8K
$56.4K
Total Liabilities
$968.0K
$894.3K
$809.6K
$1M
$1M
$964.0K
$4M
$5M
$5M
$5M
$10M
$6M
Common Stock
$2.3K
$1.5K
$1.5K
$1.5K
$13.5K
$8.8K
$6.1K
$811
$9.0K
$8.7K
$4.9K
$150.0K
Paid-in Capital
$212M
$208M
$208M
$208M
$206M
$194M
$188M
$168M
$165M
$164M
$100M
$91M
Retained Earnings
$-200M
$-197M
$-193M
$-189M
$-183M
$-177M
$-166M
$-153M
$-146M
$-142M
$-88M
$-76M
Treasury Stock
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
AOCI
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$575.7K
Stockholders' Equity
$7M
$6M
$10M
$14M
$18M
$12M
$17M
$10M
$14M
$16M
$7M
$10M
Liabilities + Equity
$8M
$7M
$11M
$15M
$20M
$13M
$22M
$14M
$19M
$21M
$17M
$16M
Shares Outstanding
2,291,056
1,542,139
1,540,684
1,516,659
13,439,612
8,745,207
6,065,441
783,865
8,717,541
4,585,800
4,585,800
139,297,282
Flusso di cassa8
Dati annuali Flusso di cassa per XBIO
Metrica
Tendenza
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
D&A
·
·
·
$0
$0
$1.0K
·
·
·
·
$56.1K
$88.7K
Stock-based Comp
$64.8K
$171.8K
$283.1K
$511.5K
$410.4K
$468.9K
$806.1K
$1M
$2M
$2M
$2M
$2M
Operating Cash Flow
$-2M
$-3M
$-4M
$-5M
$-5M
$-4M
$-6M
$-6M
$1M
$-9M
$-5M
$-13M
CapEx
·
·
·
·
·
·
·
$0
$9.3K
$16.8K
$1.7K
$57.7K
Investing Cash Flow
·
·
$0
$-500.0K
$0
$0
$2.0K
$22.5K
$-9.3K
$-16.8K
·
·
Stock Issued
$4M
$0
·
$0
$11M
$5M
$0
·
·
·
$0
$10M
Financing Cash Flow
$4M
$0
·
$0
$11M
$5M
$16M
$1M
$0
$13M
·
·
Taxes Paid
·
·
·
·
·
·
·
·
·
·
·
$0
Per Azione1
Dati annuali Per Azione per XBIO
Metrica
Tendenza
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
EPS (TTM)
$-1.58
$-2.57
$-2.71
$-4.61
$-0.55
·
·
·
·
·
·
·
Tassi di Crescita3
Dati annuali Tassi di Crescita per XBIO
Metrica
Tendenza
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue YoY
19.0%
-1.6%
48.8%
47.1%
165.6%
·
·
·
·
·
·
·
Revenue CAGR 3Y
20.4%
29.1%
79.8%
·
·
·
·
·
·
·
·
·
Revenue CAGR 5Y
46.8%
·
·
·
·
·
·
·
·
·
·
·
Valutazione (TTM)5
Dati annuali Valutazione (TTM) per XBIO
Metrica
Tendenza
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue TTM
$3M
$3M
$3M
$2M
$1M
$436.9K
$17.1K
$0
$8M
$3M
$0
$0
Net Income TTM
$-3M
$-4M
$-4M
$-7M
$-6M
$-11M
$-13M
$-7M
$-4M
$-54M
$-13M
$-14M
P/E
-1.4
-1.6
-1.3
-0.6
-23.5
·
·
·
·
·
·
·
P / Tangible Book
0.7
1.0
0.5
3.2
9.4
14.6
·
·
·
·
·
·
Earnings Yield
-72.8%
-64.4%
-78.5%
-161.8%
-4.3%
·
·
·
·
·
·
·
Conto Economico14
Dati trimestrali Conto Economico per XBIO
Metrica
Tendenza
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Revenue
$660.6K
$806.9K
$766.3K
$1M
$589.9K
$593.3K
$648.8K
$614.2K
$726.4K
$510.8K
$672.0K
$611.2K
$651.0K
$605.8K
$487.0K
$414.2K
R&D Expense
$552.0K
$661.4K
$773.4K
$756.5K
$656.6K
$879.0K
$1M
$368.0K
$933.8K
$944.3K
$975.6K
$1M
$903.2K
$595.3K
$1M
$398.8K
SG&A Expense
$1M
$647.6K
$615.9K
$815.2K
$657.8K
$656.6K
$705.7K
$745.7K
$1M
$834.9K
$952.0K
$737.2K
$946.0K
$925.7K
$857.2K
$863.2K
Operating Expenses
$2M
$1M
$1M
$2M
$1M
$2M
$2M
$1M
$2M
$2M
$2M
$2M
$2M
$2M
$2M
$1M
Operating Income
$-971.7K
$-502.1K
$-623.0K
$-544.7K
$-724.4K
$-942.4K
$-1M
$-499.5K
$-1M
$-1M
$-1M
$-1M
$-1M
$-915.2K
$-2M
$-847.8K
Interest Income
$42.1K
$45.8K
·
·
$34.2K
$39.2K
·
·
·
·
·
·
·
·
·
·
Other Non-op
$-72
$-21
$159
$4.0K
$1.5K
$78
$-7.2K
$1.5K
$-21
$52
$404
$-666
$21.1K
$4.5K
$986
$-1.7K
Income Tax
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Net Income
$-929.7K
$-456.4K
$-579.1K
$-509.9K
$-688.7K
$-903.1K
$-1M
$-436.7K
$-1M
$-1M
$-1M
$-1M
$-1M
$-856.6K
$-1M
$-804.0K
EPS (Basic)
$-0.41
$-0.20
$-0.21
$-0.33
$-0.45
$-0.59
$-0.68
$-0.28
$-0.83
$-0.78
$-0.77
$-0.69
$-0.69
$-0.56
$-2.03
$-0.56
EPS (Diluted)
$-0.41
$-0.20
$-0.21
$-0.33
$-0.45
$-0.59
$-0.68
$-0.28
$-0.83
$-0.78
$-0.77
$-0.69
$-0.69
$-0.56
$-2.03
$-0.56
Shares (Basic)
2,294,364
2,291,056
-2,924,846
1,542,139
1,542,139
1,542,139
-3,081,866
1,541,722
1,540,799
1,540,684
-3,045,766
1,532,600
1,524,717
1,516,659
-14,855,930
1,431,659
Shares (Diluted)
2,294,364
2,291,056
-2,924,846
1,542,139
1,542,139
1,542,139
-3,081,866
1,541,722
1,540,799
1,540,684
-3,045,766
1,532,600
1,524,717
1,516,659
-14,855,930
1,431,659
EBITDA
$-971.7K
$-502.1K
·
$-544.7K
$-724.4K
$-942.4K
·
$-499.5K
$-1M
$-1M
·
$-1M
$-1M
$-915.2K
·
$-847.8K
Stato Patrimoniale18
Dati trimestrali Stato Patrimoniale per XBIO
Metrica
Tendenza
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Cash & Equivalents
·
$7M
·
·
·
$5M
·
$7M
$7M
$8M
$9M
$10M
$11M
$12M
$13M
$14M
Prepaid Expense
$182.3K
$247.8K
$166.3K
$946.4K
$573.9K
$313.6K
$422.0K
$188.1K
$716.4K
$552.0K
$603.8K
$1M
$1M
$876.5K
$556.1K
$319.1K
Current Assets
$7M
$8M
$8M
$5M
$5M
$5M
$7M
$7M
$8M
$8M
$10M
$11M
$12M
$13M
$14M
$14M
Other Non-current Assets
$313.9K
$313.9K
$313.9K
$0
$0
$313.9K
$313.9K
$1M
$1M
$1M
$1M
$704.4K
$704.4K
$844.4K
$1M
$1M
Total Assets
$7M
$8M
$8M
$5M
$5M
$6M
$7M
$8M
$9M
$9M
$11M
$12M
$13M
$14M
$15M
$16M
Accounts Payable
$322.5K
$558.8K
$258.1K
$578.2K
$346.8K
$240.3K
$283.6K
$243.3K
$283.6K
$210.5K
$240.8K
$448.6K
$221.3K
$259.2K
$287.4K
$202.8K
Accrued Liabilities
·
·
$709.9K
·
·
·
$610.6K
·
·
·
$568.8K
·
·
·
$785.8K
·
Current Liabilities
$895.0K
$958.2K
$968.0K
$1M
$903.4K
$667.9K
$894.3K
$1M
$2M
$716.5K
$809.6K
$1M
$871.3K
$856.4K
$1M
$1M
Capital Leases
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
$0
Total Liabilities
$895.0K
$958.2K
$968.0K
$1M
$903.4K
$667.9K
$894.3K
$1M
$2M
$716.5K
$809.6K
$1M
$871.3K
$856.4K
$1M
$1M
Common Stock
$2.3K
$2.3K
$2.3K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$15.2K
$1.5K
$14.3K
Paid-in Capital
$212M
$212M
$212M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$207M
Retained Earnings
$-201M
$-200M
$-200M
$-199M
$-199M
$-198M
$-197M
$-196M
$-196M
$-194M
$-193M
$-192M
$-191M
$-190M
$-189M
$-188M
Treasury Stock
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
AOCI
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
Stockholders' Equity
$6M
$7M
$7M
$4M
$4M
$5M
$6M
$7M
$7M
$9M
$10M
$11M
$12M
$13M
$14M
$15M
Liabilities + Equity
$7M
$8M
$8M
$5M
$5M
$6M
$7M
$8M
$9M
$9M
$11M
$12M
$13M
$14M
$15M
$16M
Shares Outstanding
2,343,181
2,293,757
2,291,056
1,542,139
1,542,139
1,542,139
1,542,139
1,542,139
1,541,101
1,540,684
1,540,684
1,532,600
1,532,600
15,166,596
1,516,659
14,316,596
Flusso di cassa3
Dati trimestrali Flusso di cassa per XBIO
Metrica
Tendenza
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Stock-based Comp
$52.0K
$11.3K
$14.0K
$15.9K
$15.7K
$19.3K
$25.1K
$27.5K
$42.1K
$77.1K
$74.6K
$70.3K
$69.4K
$68.9K
$118.7K
$137.4K
Operating Cash Flow
$-875.5K
$-536.4K
$-242.7K
$-658.2K
$-383.8K
$-1M
$-674.0K
$-459.0K
$-525.1K
$-1M
$-793.0K
$-949.6K
$-1M
$-1M
$-750.9K
$-1M
Investing Cash Flow
·
·
·
·
·
·
·
·
·
·
·
$0
·
·
$0
$0
Redditività5
Dati trimestrali Redditività per XBIO
Metrica
Tendenza
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Operating Margin
-147.1%
-62.2%
·
-53.0%
-122.8%
-158.8%
·
-81.3%
-184.1%
-248.3%
·
-187.6%
-184.1%
-151.1%
·
-204.7%
Net Margin
-140.7%
-56.6%
·
-49.7%
-116.8%
-152.2%
·
-71.1%
-175.4%
-234.0%
·
-172.7%
-161.4%
-141.4%
·
-194.1%
EBITDA Margin
-147.1%
-62.2%
·
-53.0%
-122.8%
-158.8%
·
-81.3%
-184.1%
-248.3%
·
-187.6%
-184.1%
-151.1%
·
-204.7%
ROA
-15.1%
-6.7%
·
-7.8%
-9.6%
-11.9%
·
-4.4%
-11.7%
-10.3%
·
-7.7%
-7.2%
-5.4%
·
-4.4%
ROE
-17.7%
-7.6%
·
-9.3%
-11.6%
-13.1%
·
-4.9%
-13.2%
-11.1%
·
-8.3%
-7.8%
-5.8%
·
-4.6%
Liquidità e Solvibilità2
Dati trimestrali Liquidità e Solvibilità per XBIO
Metrica
Tendenza
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Current Ratio
7.4
7.9
·
4.6
5.9
8.2
·
7.0
5.0
11.7
·
10.5
13.8
15.0
·
13.5
Quick Ratio
·
7.7
·
·
·
7.7
·
6.8
4.6
10.9
·
9.1
12.3
14.0
·
13.2
Efficienza1
Dati trimestrali Efficienza per XBIO
Metrica
Tendenza
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Asset Turnover
0.1
0.1
·
0.2
0.1
0.1
·
0.1
0.1
0.0
·
0.0
0.0
0.0
·
0.0
Per Azione5
Dati trimestrali Per Azione per XBIO
Metrica
Tendenza
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Book Value / Share
$2.59
$3.03
·
$2.57
$2.89
$3.32
·
$4.56
$4.83
$5.63
·
$7.11
$7.75
$0.85
·
$1.01
Revenue / Share
$0.29
$0.35
·
$0.67
$0.38
$0.38
·
$0.40
$0.47
$0.33
·
$0.40
$0.43
$0.04
·
$0.03
Cash Flow / Share
·
$-0.23
·
·
·
$-0.65
·
·
·
$-0.75
·
·
·
$-0.07
·
·
Cash / Share
·
$3.20
·
·
·
$3.35
·
$4.44
$4.74
$5.08
·
$6.38
$7.00
$0.79
·
$0.97
EPS (TTM)
$-1.39
$-1.57
·
$-1.65
$-2.15
$-2.48
·
$-2.58
$-2.99
$-2.72
·
$-2.50
$-3.71
$-3.14
·
$-2.71
Valutazione (TTM)9
Dati trimestrali Valutazione (TTM) per XBIO
Metrica
Tendenza
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Revenue TTM
$3M
$3M
·
$3M
$3M
$2M
·
$2M
$2M
$2M
·
$2M
$2M
$2M
·
$2M
Net Income TTM
$-3M
$-3M
·
$-3M
$-3M
$-4M
·
$-4M
$-5M
$-4M
·
$-4M
$-5M
$-6M
·
$-6M
Market Cap
$7M
$6M
·
$5M
$6M
$4M
·
$7M
$6M
$6M
·
$8M
$5M
$62M
·
$77M
P/E
-2.1
-1.7
·
-1.9
-1.8
-1.1
·
-1.7
-1.4
-1.4
·
-2.0
-0.9
-1.3
·
-2.0
P/S
2.2
2.0
·
1.7
2.4
1.6
·
2.7
2.5
2.4
·
3.3
2.4
33.7
·
49.0
P/B
1.1
0.9
·
1.2
1.4
0.8
·
0.9
0.8
0.7
·
0.7
0.4
4.8
·
5.3
P / Tangible Book
1.1
0.9
·
1.2
1.4
0.8
·
0.9
0.8
0.7
·
0.7
0.4
4.8
·
5.3
P / Cash Flow
·
-11.5
·
·
·
-4.0
·
·
·
-5.0
·
·
·
-55.9
·
·
Earnings Yield
-47.8%
-58.6%
·
-52.5%
-54.9%
-95.0%
·
-59.7%
-73.5%
-72.2%
·
-51.0%
-113.1%
-77.3%
·
-50.5%
Bilanci
Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
2025-12-31
2024-12-31
2023-12-31
2022-12-31
2021-12-31
Ricavi
$3M
$3M
$3M
$2M
$1M
Utile netto
$-3M
$-4M
$-4M
$-7M
$-6M
EPS Diluito
$-1.58
$-2.57
$-2.71
$-4.61
$-0.55
Le Mie Metriche
La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F)
8 filer · $422K totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
Nuove posizioni
Posizioni chiuse
Aumentato
Diminuito
Variazione netta delle azioni
2
(+1 vs trimestre precedente)
0
(-5 vs trimestre precedente)
1
(0 vs trimestre precedente)
3
(+1 vs trimestre precedente)
-17K
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+
3 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
Depositante
Depositato
Partecipazione
Stato
Scopo
Deposito
CLS Therapeutics, LLC, CLS Therapeutics Ltd., Dmitry Genkin, Victor Tets, Georgy Tets, M. Scott Maguire
×3 depositi
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF
Posseduto da 1 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.